Close

Needham & Company Reiterates Buy Rating, $32 Price Target on Taysha Gene Therapies (TSHA) Apr 12, 2022 06:35AM
Taysha Gene Therapies (TSHA) PT Lowered to $32 at Needham & Company Mar 31, 2022 12:46PM
Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences Mar 23, 2022 07:00AM
Taysha Gene Therapies (TSHA) PT Raised to $47 at Needham & Company Oct 5, 2021 02:05PM
Pre-Open Stock Movers 07/16: (GLG) (AEHR) (MGI) Higher; (FGEN) (AOUT) (CRVS) Lower (more...) Jul 16, 2021 09:30AM


Jul 15, 2021 06:22PM After-Hours Stock Movers 07/15: (AEHR) (APT) (MRNA) Higher; (AOUT) (CRVS) Lower (more...)
Jul 15, 2021 04:53PM UPDATE: Needham & Company Starts Taysha Gene Therapies (TSHA) at Buy, $45 PT
Apr 5, 2021 07:00AM Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences